BioSpace News Archive

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.

4D Molecular Therapeutics a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, reported third quarter 2023 financial results and provided operational highlights.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2023 Jefferies London Healthcare Conference in London, England, on Thursday, November 16, 2023.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on January 16, 2024, to shareholders of record as of December 15, 2023.

Cencora, Inc., formerly AmerisourceBergen Corporation, announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.

Intrommune Therapeutics, Inc. will present top-line results of the Phase 1 OMEGA clinical trial during a late-breaking oral presentation at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting in Anaheim, California.

Alladapt Immunotherapeutics, Inc. announced that data from the Phase 1/2 Harmony study will be presented at the 2023 Annual Scientific Meeting of the American College of Asthma, Allergy and Immunology taking place Nov. 9-13.

Ionis Pharmaceuticals, Inc. announced positive results from an ongoing Phase 2 open-label extension study evaluating the safety and efficacy of its investigational prophylactic medicine, donidalorsen, in patients with hereditary angioedema, a rare and life-threatening genetic disease.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the first publication of a paper in Nature Communications on the development and validation of its NULISA technology.

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.